1. ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM). (22nd November 2019) Authors: Rosenthal, Mark A; Balana, Carmen; van Linde, Myra E; Sayehli, Cyrus; Fiedler, Walter M; Wermke, Martin; Massard, Christophe; Mellinghoff, Ingo K; Khasraw, Mustafa; Ang, Agnes; Rasmussen, Erik; Kast, Johannes; Stienen, Sabine; Cloughesy, Timothy F Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Communicating with brain tumor patients about driving: Are we falling short of the mark?. Issue 1 (1st April 2013) Authors: Field, Kathryn M; Guyatt, Ngaere; Fleet, Marcia; Rosenthal, Mark A; Drummond, Kate Journal: Asia-Pacific journal of clinical oncology Issue: Volume 10:Issue 1(2014:Mar.) Page Start: 92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Perioperative clinical trials for glioma: Raising the bar. (July 2021) Authors: Mweempwa, Angela; Rosenthal, Mark A; Dimou, James; Drummond, Katharine J; Whittle, James R Journal: Journal of clinical neuroscience Issue: Volume 89(2021) Page Start: 144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗